BRAF Inhibitor PF-07799933

Preferred Label : BRAF Inhibitor PF-07799933;

NCIt definition : An orally bioavailable class 1 and 2 inhibitor of the serine/threonine-protein kinase B-raf (BRAF) protein, with potential antineoplastic activity. Upon oral administration, BRAF inhibitor PF-07799933 selectively binds to and inhibits the activity of class 1 and 2 BRAF alterations. This inhibits the proliferation of tumor cells which express these BRAF alterations. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) signaling pathways, which may be constitutively activated due to BRAF gene mutations. Mutated forms and fusions of BRAF are associated with a number of neoplastic diseases.;

Molecule name : ARRY-440; ARRY 440; PF-07799933; PF 07799933;

NCI Metathesaurus CUI : CL1905425;

Details

Origin ID

C191953;

UMLS CUI

C5777127;

Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Enzyme Inhibition [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Inhibition of Cell Proliferation [NCIt concept]
- Positive Regulation of Apoptosis [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Serine/Threonine-Protein Kinase B-Raf [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients